Skip to the page content
Your donations
Passes our checks

International Society for Cellular Therapy

EIN 52-1809771 · Canada

Public records show a registered, tax-exempt organization in good standing.

LegitimacyPassesRegistration and standingFinancial healthStrong96 out of 100GovernanceStrong100 out of 100Impact evidenceDescribes programsHow well its results are evidenced

What it says it does

SEE SCHEDULE O.THE MISSION OF INTERNATIONAL SOCIETY OF CELLULAR THERAPY (ISCT) IS TO DRIVE CLINICAL TRANSLATION OF CELL AND GENE THERAPIES WORLDWIDE. ISCT IS A GLOBAL SOCIETY OF CLINICIANS, REGULATORS, TECHNOLOGISTS, AND INDUSTRY PARTNERS WORKING TO TRANSLATE CELLULAR THERAPY INTO SAFE AND EFFECTIVE THERAPIES TO IMPROVE PATIENTS' LIVES.

Income
$7.5 million
Spending
$4.1 million
Spent on programs
87%
Reserves
30.9 months of spending
Largest source of income
fees for its services, 92%
Employees
0
Volunteers
400
Highest pay
$305,828, chief executive officer

Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Financial health

Strong: 96 out of 100.

  • Reserves

    35 of 35

    Spendable reserves would cover 30.9 months of spending.

  • Debt

    16 of 20

    It owes 17% of what it owns.

  • Living within its means

    15 of 15

    Income exceeded spending by 45% of income.

  • Income trend

    15 of 15

    Income rose 29% on the year before.

  • Spending floor

    15 of 15

    87% of spending went to programs.

Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Governance

Strong: 100 out of 100.

  • Independent board

    25 of 25

    15 of 18 voting board members are independent.

  • Conflict of interest policy

    15 of 15

    Has a written conflict of interest policy.

  • Whistleblower policy

    8 of 8

    Has a written whistleblower policy.

  • Record keeping policy

    7 of 7

    Has a written policy on keeping and destroying records.

  • Board minutes

    5 of 5

    Keeps minutes of board meetings.

  • Board sees the tax return

    10 of 10

    Gave the board a copy of this return before filing it.

  • Pay set independently

    5 of 5

    Sets its chief executive's pay through independent review and comparison.

  • Independent check of accounts

    15 of 15

    Its accounts were audited by an independent accountant.

  • No reported misuse

    10 of 10

    Reports no diversion of assets, excess benefits or loans to insiders.

Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Impact evidence

Describes programs. Its tax return describes what it does but we have found no measurable results in it.

Programs described in its return (4)
  1. $2.1 million spent. ISCT ANNUAL AND REGIONAL MEETINGS COVER TOPICS THAT SPAN THE FULL TRANSLATIONAL PIPELINE FOR CELL AND GENE THERAPY, INCLUDING SCIENTIFIC AND CLINICAL ADVANCES, MANUFACTURING AND PROCESS DEVELOPMENT, REGULATORY AND POLICY, COMMERCIALIZATION AND ACCESS, AND ETHICS. THE ANNUAL MEETING TOPICS ARE MORE GLOBAL IN FOCUS, WHEREAS THE REGIONAL MEETINGS FOCUS ON TOPICS THAT ARE RELEVANT TO THE SPECIFIC HOST REGION. THE SCIENTIFIC PROGRAMS ARE CURATED BY SUBJECT-MATTER EXPERTS AND ARE EDUCATION-FOCUSED WITH LEARNING OBJECTIVES. THE ISCT 2024 ANNUAL CONFERENCE WAS HELD IN VANCOUVER, BRITISH COLUMBIA, CANADA, WITH APPROXIMATELY 2,700 ATTENDEES. THE ISCT EUROPE 2024 REGIONAL CONFERENCE WAS HELD IN STOCKHOLM, SWEDEN, WITH APPROXIMATELY 450 ATTENDEES.
  2. $733,731 spent. MEMBER BENEFITS INCLUDE: ACCESS TO EDUCATIONAL RESOURCES (WEBINARS, ACCREDITED TRAINING PROGRAMS), ELIGIBILITY TO PARTICIPATE IN ONE OF 40+ EXPERT-LED COMMITTEES, ACCESS TO CYTOTHERAPY, THE SOCIETY'S PEER- REVIEWED JOURNAL, REDUCED RATES TO ISCT ANNUAL AND REGIONAL MEETINGS, NETWORKING, AND MENTORSHIP OPPORTUNITIES FOR CAREER DEVELOPMENT. INDIVIDUALS MAY JOIN ISCT THROUGH THREE DIFFERENT MEMBERSHIP CATEGORIES: INDIVIDUAL, LABORATORY, INDUSTRY COMMUNITY. THE AGGREGATE AVERAGE MEMBERSHIP RETENTION RATE IS 78%. IN 2024, THERE WERE APPROXIMATELY 4,500 GLOBAL MEMBERS.
  3. $409,007 spent. WORKFORCE TRAINING AND DEVELOPMENT IDENTIFIES, DEVELOPS, AND DELIVERS ISCT TRAINING AND DEVELOPMENT PROGRAMS TO ADDRESS CURRENT SKILLS GAPS IN CELL AND GENE THERAPY (CGT) TRANSLATION. THE GOALS OF THE ISCT INSTITUTE OF TRAINING AND DEVELOPMENT ARE TO CREATE GLOBALLY ACCREDITED CGT TRAINING PROGRAMS THROUGH QUALITY CONTENT, STANDARDS, AND EXPERTISE, AND TO PROVIDE A LONGITUDINAL APPROACH FOR LONG-TERM CAREER DEVELOPMENT. IN 2024, THERE WERE 442 PARTICIPANTS IN 10 COURSES COVERING A VARIETY OF TOPICS.
  4. $335,185 spent. CYTOTHERAPY, THE OFFICIAL JOURNAL OF ISCT, PUBLISHES NOVEL AND INNOVATIVE RESULTS FROM HIGH QUALITY SCIENTIFIC AND CLINICAL STUDIES IN THE FIELDS OF CELL AND GENE THERAPY. IN ADDITION TO SHORT REPORTS AND FULL-LENGTH ARTICLES, THE JOURNAL ALSO ACCEPTS EDITORIALS ON EMERGING TRENDS AND POTENTIAL CONTROVERSIES IN THE FIELD AND REVIEW ARTICLES SUMMARIZING IMPORTANT AREAS OF CELL AND GENE THERAPY RESEARCH THAT ARE TOPICAL AND/OR CHALLENGE EXISTING PARADIGMS IN THE FIELD.CYTOTHERAPY CONSIDERS MANUSCRIPTS EXPLORING THE FOLLOWING TOPICS:- GENE, CELL (INCLUDES STEM CELLS AND IPSCS) AND EVIDENCE-BASED THERAPIES- REGULATORY FRAMEWORKS AND POLICY ISSUES IN CGT (CELL AND GENE THERAPY)- NOVEL AND INNOVATIVE RESULTS FROM BASIC, TRANSLATIONAL, AND CLINICAL STUDIES IN CGT- IMPORTANT ADVANCES IN CELL/GENE-BASED PRODUCT MANUFACTURING, COMMERCIALIZATION, AND PATIENT ACCESS - CLINICAL STUDIES EVALUATING THE SAFETY AND EFFICACY OF CELL AND GENE THERAPIESCYTOTHERAPY DOES NOT PUBLISH MANUSCRIPTS ON THE FOLLOWING TOPICS:- CASE STUDIES UNLESS THEY ARE OF UNUSUAL SIGNIFICANCE TO THE FIELD- BASIC/TRANSLATIONAL STUDIES EXPLORING THE ROLE OF LNCRNAS, CIRCRNAS, AND MIRNAS IN DISEASE PATHOPHYSIOLOGY- STUDIES DESCRIBING SIGNALING PATHWAYS IMPLICATED IN CANCER

Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate

Legitimacy checks

  1. Is it registered with the IRS? Passed.

    Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.

  2. Has the IRS revoked its tax-exempt status? Passed.

    Not on the IRS automatic revocation list.

    Source: Automatic revocation of exemption list, Internal Revenue Service, file dated September 30, 2026.

  3. Are donations tax-deductible? Passed.

    On the IRS list of organizations eligible to receive tax-deductible contributions.

    Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated September 10, 2026.

  4. Is it keeping up with its IRS filings? Passed.

    Most recent return on file covers the year ending December 2024.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.

  5. How long has it been tax-exempt? Passed.

    Recognized by the IRS since November 1994.

    Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.

  6. Is it in good standing with state regulators? Passed.

    Not on California's list of charities barred from soliciting. Other states are not yet checked.

    Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated October 7, 2026.

Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.